Oncimmune Appoints Lung Cancer KOL As Chief Medical Officer
This article was originally published in Clinica
Dr James Jett is to join Oncimmune, a company that has developed an early-stage lung cancer test, as chief medical officer on Jan 1. He is currently Professor of Medicine in the Division of Oncology at National Jewish Health in the US; he has been the principal investigator on the National Jewish Health study on Oncimmune’s blood-based autoantibody assay for early-stage lung cancer, Early CDT-Lung. In his role at the company, Jett will be responsible for overseeing all the R&D activities, as the firm continues to expand commercialization EarlyCDT-Lung. Oncimmune toldClinica earlier this year that it was ramping up US sales of the test. The firm is also developing tests for liver and ovarian cancers.
Register for our free email digests: